Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates
Ultragenyx (RARE) came out with a quarterly loss of $1.52 per share versus the Zacks Consensus Estimate of a loss of $1.64. This compares to loss of $2.25 per share a year ago.
Ultragenyx (RARE) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans
Ultragenyx (RARE) reaches alignment with the FDA regarding the pivotal phase III study design and endpoints for GTX-102 for Angelman syndrome, which is scheduled to be initiated later this year.
Ultragenyx (RARE) to Seek Accelerated Nod for Rare Disease Drug
Following a fruitful meeting with the FDA, Ultragenyx (RARE) plans to seek accelerated approval for UX111 for the treatment of Sanfilippo syndrome type A.
Ultragenyx (RARE) Moves 7.8% Higher: Will This Strength Last?
Ultragenyx (RARE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Ultragenyx (RARE) Posts New Data From Bone Disease Study
Ultragenyx's (RARE) pipeline candidate setrusumab shows sustained reductions in fracture rates in patients with osteogenesis imperfecta in new data from the Orbit study.
Ultragenyx: Modest Sales Growth, With Multiple Inflection Points Approaching
Ultragenyx Pharmaceutical Inc. revenues from regulatory approved drugs in Q1 of 2024 were $109 million, representing sales growth of 8% compared to the same time period in 2023. Setrusumab is an anti-sclerostin monoclonal antibody being developed for the treatment of patients with osteogenesis imperfecta. DTX-401 is another promising program in the pipeline being developed for the treatment of patients with glycogen storage disease type Ia.
Ultragenyx (RARE) DTX401 Meets Goals in Metabolic Disorder Study
Ultragenyx (RARE) reports meeting primary and secondary endpoints in the late-stage study of its investigational gene therapy, DTX401, to treat glycogen storage disease type Ia.
